acebutolol has been researched along with Iron Metabolism Disorders in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allard, M; Bernimoulin, M; Guidard, C; Ozsahin, H; Schaeppi, M; van den Ouweland, F | 1 |
| Aiello, A; Berto, P; Conti, P; Panichi, V; Rosati, A | 1 |
| Mezzacasa, A; Oertel, W; Roubert, B; Trenkwalder, C; Virgin, G; Winkelmann, J | 1 |
| Bourguignon, S; Caranhac, G; Champs, FO; Cohen-Solal, A; Faller, M; Levesque, K; Moutier, H | 1 |
| Abu-Own, H; Anker, SD; Colet, JC; Filippatos, G; Jouhra, F; Mori, C; Okonko, DO; Ponikowski, P; Suki, C | 1 |
1 review(s) available for acebutolol and Iron Metabolism Disorders
| Article | Year |
|---|---|
Economic impact of ferric carboxymaltose in haemodialysis patients
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Ferric Oxide, Saccharated; Hematinics; Humans; Iron Deficiencies; Iron Metabolism Disorders; Maltose; Renal Dialysis | 2020 |
2 trial(s) available for acebutolol and Iron Metabolism Disorders
| Article | Year |
|---|---|
Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial.
Topics: Aged; Aged, 80 and over; Female; Ferric Compounds; Ferritins; Hematinics; Humans; Iron Metabolism Disorders; Male; Maltose; Middle Aged; Prospective Studies; Restless Legs Syndrome; Single-Blind Method; Time Factors; Treatment Outcome | 2017 |
Effect of ferric carboxymaltose on calculated plasma volume status and clinical congestion: a FAIR-HF substudy.
Topics: Aged; Aged, 80 and over; Chronic Disease; Double-Blind Method; Female; Ferric Compounds; Heart Failure; Humans; Iron Deficiencies; Iron Metabolism Disorders; Male; Maltose; Middle Aged; Plasma Volume | 2019 |
2 other study(ies) available for acebutolol and Iron Metabolism Disorders
| Article | Year |
|---|---|
Intravenous ferric carboxymaltose for iron deficiency anemia or iron deficiency without anemia after poor response to oral iron treatment: Benefits and risks in a cohort of 144 children and adolescents.
Topics: Administration, Intravenous; Adolescent; Anemia, Iron-Deficiency; Child; Child, Preschool; Female; Ferric Compounds; Follow-Up Studies; Humans; Infant; Iron Metabolism Disorders; Male; Maltose; Prognosis; Retrospective Studies | 2020 |
Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France.
Topics: Administration, Intravenous; Aged; Chronic Disease; Cost Savings; Ferric Compounds; France; Heart Failure; Humans; Iron Deficiencies; Iron Metabolism Disorders; Maltose; Models, Economic | 2019 |